再発または難治性のB細胞非ホジキンリンパ腫患者の治療におけるオビヌツズマブ、ベネトクラクス、およびレナリドマイド
再発および難治性 B 細胞非ホジキンリンパ腫におけるオビヌツズマブ、ベネトクラクス、およびレナリドマイドの第 I 相試験
This phase I study studies the side effects and best dose of venetoclax and lenalidomide when given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or not responding to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving obinutuzumab, venetoclax, and lenalidomide may work better in treating patients with B-cell non-Hodgkin lymphoma.
調査の概要
状態
条件
詳細な説明
PRIMARY OBJECTIVES:
I. To determine the dose limiting toxicity (DLT) and the recommended phase 2 dose (RP2D), which is typically the maximum tolerated dose (MTD), of the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
SECONDARY OBJECTIVES:
I. To estimate the overall objective response rate to the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refractory B-cell NHL.
II. To estimate the duration of response and 2 year progression-free survival associated with obinutuzumab, venetoclax, and lenalidomide treatment in patients with relapsed and refractory B-cell NHL.
III. To define the qualitative and quantitative toxicities of the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refractory B-cell NHL.
OUTLINE: This is a dose-escalation study of venetoclax and lenalidomide.
Patients receive lenalidomide orally (PO) on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab intravenously (IV) on days 1, 8, and 15 of course 1 and on day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 4 weeks, every 3 months for 2 years, then every 6 months.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory University
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Comprehensive Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
-
Prior venetoclax or other BCL-2 family inhibitors or prior lenalidomide is not permitted
-
Creatinine clearance >= 50 ml/min using a 24 hour creatinine clearance or estimated creatinine clearance using the Cockcroft-Gault equation
-
Bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
-
Absolute neutrophil count (ANC) >= 1000/mm^3
-
Platelet >= 75,000/mm^3
- Unless related to bone marrow involvement with disease, in which case platelets must be >= 50,000/mm^3
-
Recovery to =< grade 1 from all toxicities associated with prior therapy except alopecia
-
Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL) of any of the following subtypes recognized by the World Health Organization (WHO) classification: Burkitt lymphoma, B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, or follicular lymphoma; patients with evidence of histological transformation to diffuse large B-cell lymphoma from indolent NHL are eligible
-
At least one prior therapy; prior autologous stem cell transplant is permitted; patients with aggressive lymphoma who have not received high-dose therapy (HDT)/autologous stem cell transplantation (ASCT) must be ineligible for HDT/ASCT; prior allogeneic stem cell transplant is not permitted
-
Patients with indolent lymphoma must have an indication for treatment in the opinion of the investigator
-
Radiographically measurable disease by computed tomography (CT) scan, defined as at least one node > 1.5 cm in size or assessable disease
-
All study participants must be registered into the mandatory Revlimid risk evaluation and mitigation strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
-
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
-
Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin (ASA) may use low molecular weight heparin or equivalent)
-
EXPANSION COHORT
-
Cohort A will enroll 10 patients with a diagnosis of diffuse large B-cell lymphoma; B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (double hit lymphoma), Burkitt lymphoma, and transformed lymphoma
-
Cohort B will enroll 20 patients with a diagnosis of follicular lymphoma, grade 1-2 and 3A; grade 3B is excluded; diagnoses made by a fine needle aspirate or bone marrow biopsy alone are not permitted
Exclusion Criteria:
-
Patients with active central nervous system (CNS) involvement with lymphoma are not eligible
-
Patients with human immunodeficiency virus (HIV) or human T-cell leukemia virus 1 (HTLV-1) are not eligible
-
Evidence of active hepatitis B infection, based on positive surface antigen or hepatitis B deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), or active hepatitis C infection; patients who are hepatitis B core antibody positive must take prophylaxis with lamivudine or equivalent and be willing to undergo monthly hepatitis B DNA PCR testing
-
Prior allogeneic stem cell transplant is not permitted
-
Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of venetoclax or lenalidomide
-
Any chemotherapy or radiation therapy within 4 weeks of the first dose of study drug
-
Patients may take steroids for disease control up to 24 hours prior to study enrollment
-
Any illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of venetoclax and lenalidomide, or put the study outcomes at undue risk
-
A cardiovascular disability status of New York Heart Association class >= 2
-
History of severe allergic reactions to humanized monoclonal antibodies
-
History of other malignancy that could affect compliance with the protocol or interpretation of results; patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible; patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded; individuals in documented remission without treatment for >= 2 years prior to enrollment may be included at the discretion of the investigator
-
Known hypersensitivity to any of the study drugs or analogs
-
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior study therapy
-
Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin)
-
Received the following agents within 7 days prior to the first dose of venetoclax:
- Strong and moderate CYP3A inhibitors
- Strong and moderate CYP3A inducers
- Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax
-
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
-
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
-
Recent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosis
-
Malabsorption syndrome or other condition that precludes enteral route of administration
-
Known allergy to both xanthine oxidase inhibitors and rasburicase
-
Pregnant or lactating, or intending to become pregnant during the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (lenalidomide, venetoclax, obinutuzumab)
Patients receive lenalidomide PO on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1, and day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. |
Given PO
他の名前:
Given PO
他の名前:
Given IV
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
MTD defined as the highest level at which no more than 6 patients experience a DLT assessed by National Cancer Institute Common Terminology Criteria of Adverse Events version 4
時間枠:Up to 28 days
|
The recommended phase 2 dose (RP2D), which is typically the maximum tolerated dose (MTD), of the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). |
Up to 28 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective response rate (ORR) defined as the proportion of patients achieving a complete or partial, response according to the Lugano Lymphoma Response Criteria
時間枠:Up to 3 years
|
ORR will be reported with a 95% binomial confidence interval. |
Up to 3 years
|
|
Progression-free survival
時間枠:From course 1 day 1 to the date of the event (i.e., death or disease progression), assessed up to 2 years
|
PFS will be estimated using the method of Kaplan-Meier. Median PFS and 2-year PFS estimates will be reported with 95% confidence intervals. If applicable, a sensitivity analysis of PFS will include any eligible patient who receives at least one dose of study treatment (i.e. venetoclax alone without beginning the combination regimen). |
From course 1 day 1 to the date of the event (i.e., death or disease progression), assessed up to 2 years
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Beth Christian, MD、Ohio State University Comprehensive Cancer Center
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 免疫系疾患
- 感染症
- ウイルス病
- 組織型別の新生物
- DNAウイルス感染症
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫、非ホジキン
- リンパ腫
- エプスタイン-バーウイルス感染症
- ヘルペスウイルス感染症
- 腫瘍ウイルス感染症
- ヘミックおよびリンパ疾患
- リンパ腫、B細胞
- リンパ腫、大型B細胞、びまん性
- バーキットリンパ腫
- リンパ腫、濾胞性
- リンパ腫、B細胞、辺縁帯
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- カルボン酸
- ピペリジン
- フタリミド
- フタル酸
- 酸、炭素環
- ピペリドン
- イソインドール
- レナリドミド
- ベネトクラックス
- オビヌツズマブ
その他の研究ID番号
- OSU-16187
- NCI-2016-01723 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。